Skip to content

Korea Equity Lens

  • About
  • IR Room
  • Research
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • EV & Battery
    • Automotive
    • Energy
    • Robotics
    • Shipbuilding
  • Toggle search form
  • [Research] Samsung Electro-Mechanics (009150) – SK Securities | MLCC ASP Rise · FCBGA Margin Expansion · Earnings Upward Revision / 2026-07-31 Research
  • [Research] SK hynix (000660 / SKHY) – Kiwoom | Commodity Memory Pricing · Server Demand · Earnings Upgrades / 2026-01-30 Research
  • [Research] Alteogen (196170) – Hana Securities | ALT-B4 Differentiation Potential · Enhanze Biosimilar Concerns Dispelled · Qlex Revenue Visibility / 2026-07-15 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | ADR Listing · HBM4 · Valuation Re-rating / 2026-07-07 Research
  • [Research] SK hynix (000660 / SKHY) – Shinhan | Ultra-Low Inventory · Supply Shortage · Earnings Rebound / 2026-07-30 Research
  • [Research] Samsung Biologics (207940) – iM Securities | US Site Operation · K-CDMO Policy Support · Order Pipeline Optimization / 2026-04-23 Research
  • [Research] Samsung Electro-Mechanics (009150) – Shinhan Securities | Silicon Capacitor · ASP Expansion · Valuation Re-rating / 2026-05-26 Research
  • [Research] LIG D&A (079550) – Eugene Investment & Securities | Non-Cheongung Potential · High-margin Legacy Defense · Earnings Surprise / 2026-05-08 Research

[Research] SK hynix (000660 / SKHY) – Shinhan | Supply Constraints · Memory Pricing · Earnings Growth / 2026-05-21

Posted on May 21, 2026August 24, 2026 By ksb220805@gmail.com

Brokerage : Shinhan Investment Corp.

Market: KOSPI (000660)

Analyst : Hyung-tae Kim / RA: Hye-su Song

Investment Rating : BUY (Maintained)

Target Price : KRW 3,800,000 (Upgraded)

Core Momentum : Persistent supply-demand imbalances and expanding memory applications are expected to prolong price increases across DRAM and NAND, driving accelerated second-half earnings growth and sustaining industry-leading profitability.

📊 1. [Valuation & Key Financial Metrics]

  • Investment Judgment: BUY (Maintained) / Target Price: KRW 3,800,000 (Upgraded)
  • Upside Potential: 117.8% / Current Price (May 20): KRW 1,745,000
  • Market Capitalization: KRW 1,243,665.6 billion / Shares Outstanding (Float Ratio): 712.7 million (74.9%)
  • 52-Week High / Low: KRW 1,976,000 / KRW 196,900 / 60-Day Average Trading Value: KRW 5,804,616 million / Foreign Ownership: 51.9%
  • Major Shareholders: SK Square and 8 others 20.5%, National Pension Service 7.5%
  • FY 2026F Estimates: Revenue KRW 352,473.1 billion, Operating Profit KRW 266,930.6 billion, Net Income KRW 222,645.3 billion, PER 5.6x, ROE 96.5%, PBR 3.6x, EV/EBITDA 4.0x, Dividend Yield 0.2%
  • FY 2027F Estimates: Revenue KRW 527,540.9 billion, Operating Profit KRW 405,776.4 billion, Net Income KRW 321,141.9 billion, PER 3.9x, ROE 64.5%, PBR 1.9x, EV/EBITDA 2.2x, Dividend Yield 0.6%

🚀 2. [Market Opportunities & Business Outlook]

  • Severe supply-demand imbalances are unlikely to ease in the near term, and excess demand environments are intensifying due to new memory application diversifications in 2H26, making price trends surpassing past memory up-cycles a reality.
  • Annual revenue for 2026 is projected at KRW 352.5 trillion (+262.8% YoY) and operating profit at KRW 266.9 trillion (+465.5% YoY), with divisional operating profit estimated at KRW 210.7 trillion for DRAM and KRW 56.4 trillion for NAND.
  • Second-half revenue and operating profit are expected to grow by 53.7% and 59.4% respectively compared to the first half, sustaining top-tier profitability within the semiconductor industry with gross profit margins continuing above 80%.
  • The target price has been raised by 100% to KRW 3,800,000, applying a target PBR of 5.8x—matching North American peers—to a 12-month forward BPS of KRW 646,077.

📝 Editor’s Comment (Perspective & Thesis Verification)

The analyst evaluates SK hynix as a prime beneficiary of prolonged price uptrends across all products, fueled by supply constraints and application diversifications. This perspective emphasizes that the company has entered a phase of maximized earnings momentum and exceptional profitability that fully justifies valuation multiples matching North American peers (PBR 5.8x).

To determine whether this investment thesis is actively unfolding, key monitoring items include tracking whether projected second-half earnings growth (revenue +53.7%, operating profit +59.4% vs. 1H) materializes, and verifying if materialized HBM price hikes and expanded eSSD profit contributions translate into actual margin expansion. These developments can be tracked through quarterly and annual earnings releases, official corporate IR materials, and regulatory filings.

📢 Disclaimer & Source

Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)

Search by
Company Name or Stock Ticker.
Research, Semiconductors

Post navigation

Previous Post: [Research] LigaChem Biosciences (141080) – iM Securities | Clinical Data · Pipeline Progress · Tech Transfer / 2026-05-21
Next Post: [Research] Samsung Electro-Mechanics (009150) – iM Securities | Silicon Capacitor LTA · Fabless Model · SOTP Re-rating / 2026-05-21

Related Posts

  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Big Tech Backlogs · Memory Supply Tightness · Earnings Growth / 2026-07-14 Research
  • [Research] LigaChem Biosciences (141080) – Shinhan Securities | ConjuALL · Clinical Milestones · Big Pharma L/O / 2026-03-24 Research
  • [Research] LigaChem Biosciences (141080) – iM Securities | Platform Valuation · Pipeline Milestones · Deal Expansion / 2025-08-12 Research
  • [Research] Samsung Biologics (207940) – IBK Securities | US Operations · Plant 5 Ramp-up · Peptide Expansion / 2026-07-24 Research
  • [Research] SK hynix (000660 / SKHY) – Daishin | Memory ASP · Earnings Upgrades · Valuation Appeal / 2026-03-16 Research
  • [Research] SK hynix (000660 / SKHY) – Kyobo | AI Server Demand · Memory ASP · High-Value Product Mix / 2026-01-30 Research
  • [Research] LigaChem Biosciences (141080) – iM Securities | Platform Valuation · Pipeline Milestones · Deal Expansion / 2025-08-12 Research
  • [IR] SK hynix (000660 / SKHY) – Q4 2025 Earnings Presentation / 2026-01-29 IR Room
  • [Research] Celltrion (068270) – DS Investment & Securities | 2nd-Gen Biosimilar Penetration · COGS Ratio Stabilization · Global Capacity Expansion / 2026-05-07 Research
  • [Research] Celltrion (068270) – Yuanta Securities | New Biosimilar Growth · Facility Expansion · CMO Capacity Readiness / 2026-05-07 Research
  • [IR] Samsung Electronics (005930) – Q2 2026 Earnings Presentation / 2026-07-30 IR Room
  • [Research] Samsung Electro-Mechanics (009150) – Hana Securities | AI Demand · Supply Tightness · Margin Expansion / 2026-08-11 Research
  • [Research] Hanwha Ocean (042660) – iM Securities | Merchant Profit Surprise · Special Ship Sentiment · Valuation De-rating / 2026-07-28 Research
  • [Research] LIG D&A (079550) – DS Investment & Securities | Order Expansion · Iraq Cheongung-II Mass Production · Long-term Earnings Growth / 2026-08-07 Research

Copyright © 2026 Korea Equity Lens.

Powered by PressBook News Dark theme